Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Surgeon General
  • Cigna’s ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

TRENDING TOPICS:

  • Surgeon General
  • Cigna's ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Mar 30 2018

Full Issue

Watchdog Finds FDA Properly Conducted Review Of Abortion Pill When Relaxing Guidelines

The FDA's decision to lower the dosage to 200 milligrams from 600 milligrams, decrease the number of visits a woman must make to her doctor to two from three, and extend the amount of time to take the drug from seven weeks to 10 weeks had drawn fire from anti-abortion activists and Republicans.

Stat: Guidelines For Abortion Pill Were Properly Eased, Report Finds

A congressional watchdog agency has concluded the Food and Drug Administration properly conducted a review of the controversial Mifeprex abortion pill before relaxing usage guidelines two years ago, a move that prompted complaints by some lawmakers and anti-abortion activists that the shift was politically motivated. (Silverman, 3/29)

In other women's health news —

The Hill: Senate Dems Say Changes To Family Planning Program Could Undercut Access To Care

Recent changes to the Title X family planning program for low-income women and men could undercut access to reproductive health care, Senate Democrats argued in a letter to the Trump administration Thursday. In a funding announcement released last month, the Department of Health and Human Services (HHS) said grantees should be able to provide primary health services, as well as reproductive health services. (Hellmann, 3/29)

Nashville Tennessean: Senate Votes To Ban TennCare Funds From Going To Health Care Providers That Perform Abortions

The Tennessee Senate voted 24-2 on Thursday to ban any TennCare funds from going to health care providers that perform elective abortions. While no funds from TennCare, the state's Medicaid agency, directly fund abortions currently, sponsor Sen. Mike Bell, R-Riceville, said the purpose of the measure is to prevent any taxpayer dollars from indirectly funding abortions as well. (Buie, 3/29)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 1
  • Thursday, April 30
  • Wednesday, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF